Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Bondarenko, I.Sezer, A.Kilickap, S.Gumus, M.Ozguroglu, M.Gogishvili, M.Turk, H. M.2024-06-122024-06-1220211556-08641556-1380https://hdl.handle.net/20.500.14551/23528[Abstract Not Available]eninfo:eu-repo/semantics/closedAccessRandomised Controlled TrialsPhase II And III Clinical TrialsImmune Checkpoint InhibitorsClinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1Conference Object1610S951S951Q1WOS:000709606500217